NanoHeal
Helping blood vessels heal more naturally after treatment for peripheral artery disease
Why it matters
For people living with PAD, keeping the treated artery open could mean fewer repeat procedures and less interruption to everyday life.
The opportunity
When an artery narrows again
Peripheral artery disease (PAD) narrows the arteries that supply blood to the legs. It can make walking painful and increase the risk of heart attack, stroke and limb-threatening complications. Balloon and stent procedures can restore blood flow, but the treated artery may narrow again as it heals.
Nanomedx is developing NanoHeal for delivery during angioplasty. The aim is to help the treated vessel stay open by delivering an anti-inflammatory biologic at the treatment site, rather than relying on a cytotoxic drug to suppress healing. The system combines:
- a proprietary nanoparticle platform developed in NSW that increases local retention of therapy within diseased blood vessels,
- a naturally occurring human anti-inflammatory biologic (interleukin-10) designed to promote healing and reduce vessel scarring, and
- a specialised balloon catheter that delivers the therapy directly to the treatment site during a standard angioplasty procedure.
The treatment is intended to fit into the angioplasty workflow doctors already use. A dedicated balloon catheter delivers the biologic to the vessel wall during the procedure.
Sources
- 1. Laird JR, et al. Long-term clinical effectiveness of a drug-coated balloon for the treatment of femoropopliteal lesions: five-year outcomes from the IN.PACT SFA randomized trial. Circ Cardiovasc Interv. 2019;12(6):e007702.
- 2. Song P, et al. Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. Lancet Glob Health. 2019;7(8):e1020–e1030.
- 3. Fowkes FGR, et al. Peripheral artery disease: epidemiology and global perspectives. Nat Rev Cardiol. 2017;14(3):156–170.
- 4. Grand View Research. Peripheral artery disease market size, share & trends analysis report, 2024–2033.